Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
Clinical trials
Year: 2018, Jahrgang: 16, Heft: 1, Pages: 20-31 |
| ISSN: | 1740-7753 |
| DOI: | 10.1177/1740774518807160 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1177/1740774518807160 Verlag, Volltext: https://jhu.pure.elsevier.com/en/publications/developing-a-risk-based-composite-neurologic-outcome-for-a-trial- 
|
| Verfasserangaben: | James F. Casella, Robert J. Adams, Donald J. Brambilla, John Strouse, Pia Maier, Rachel Dlugash, Radhika Avadhani, Krista Vermillion, James A. Tonascia, Jenifer H. Voeks, Daniel F. Hanley, Richard Thompson, and Harold P. Lehmann; for the HU Prevent Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662569742 | ||
| 003 | DE-627 | ||
| 005 | 20230426172425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190329r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1740774518807160 |2 doi | |
| 035 | |a (DE-627)1662569742 | ||
| 035 | |a (DE-599)KXP1662569742 | ||
| 035 | |a (OCoLC)1341205890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Casella, James F. |e VerfasserIn |0 (DE-588)1181264308 |0 (DE-627)1667051458 |4 aut | |
| 245 | 1 | 0 | |a Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease |c James F. Casella, Robert J. Adams, Donald J. Brambilla, John Strouse, Pia Maier, Rachel Dlugash, Radhika Avadhani, Krista Vermillion, James A. Tonascia, Jenifer H. Voeks, Daniel F. Hanley, Richard Thompson, and Harold P. Lehmann; for the HU Prevent Investigators |
| 264 | 1 | |c 2019 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published November 14, 2018 | ||
| 500 | |a Gesehen am 29.03.2019 | ||
| 534 | |c 2018 | ||
| 700 | 1 | |a Maier, Pia |e VerfasserIn |0 (DE-588)1175594067 |0 (DE-627)1046865188 |0 (DE-576)516358847 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical trials |d Thousand Oaks, Calif. : Sage, 2004 |g 16(2019), 1, Seite 20-31 |h Online-Ressource |w (DE-627)393748383 |w (DE-600)2159773-X |w (DE-576)11714360X |x 1740-7753 |7 nnas |a Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease |
| 773 | 1 | 8 | |g volume:16 |g year:2019 |g number:1 |g pages:20-31 |g extent:12 |a Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease |
| 856 | 4 | 0 | |u https://doi.org/10.1177/1740774518807160 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://jhu.pure.elsevier.com/en/publications/developing-a-risk-based-composite-neurologic-outcome-for-a-trial- |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190329 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1175594067 |a Maier, Pia |m 1175594067:Maier, Pia |d 50000 |e 50000PM1175594067 |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1662569742 |e 3417503493 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["First published November 14, 2018","Gesehen am 29.03.2019"],"recId":"1662569742","language":["eng"],"person":[{"given":"James F.","family":"Casella","role":"aut","roleDisplay":"VerfasserIn","display":"Casella, James F."},{"roleDisplay":"VerfasserIn","display":"Maier, Pia","role":"aut","family":"Maier","given":"Pia"}],"title":[{"title":"Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease","title_sort":"Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease"}],"physDesc":[{"extent":"12 S."}],"relHost":[{"id":{"issn":["1740-7753"],"zdb":["2159773-X"],"eki":["393748383"]},"origin":[{"publisher":"Sage ; Hodder Arnold","dateIssuedKey":"2004","dateIssuedDisp":"2004-","publisherPlace":"Thousand Oaks, Calif. ; London"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Clinical trials","title":"Clinical trials","subtitle":"journal of the Society for Clinical Trials"}],"part":{"year":"2019","pages":"20-31","issue":"1","volume":"16","text":"16(2019), 1, Seite 20-31","extent":"12"},"pubHistory":["1.2004 -"],"recId":"393748383","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell diseaseClinical trials","note":["Gesehen am 03.12.13"]}],"name":{"displayForm":["James F. Casella, Robert J. Adams, Donald J. Brambilla, John Strouse, Pia Maier, Rachel Dlugash, Radhika Avadhani, Krista Vermillion, James A. Tonascia, Jenifer H. Voeks, Daniel F. Hanley, Richard Thompson, and Harold P. Lehmann; for the HU Prevent Investigators"]},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"id":{"doi":["10.1177/1740774518807160"],"eki":["1662569742"]}} | ||
| SRT | |a CASELLAJAMDEVELOPING2019 | ||